Insulet Corp. (NSDQ:PODD) inked a Canadian distribution deal with GlaxoSmithKline plc (NYSE:GSK) for its OmniPod insulin management system.
The deal gives the British pharma giant — stung by recent problems with its Avandia diabetes drug — exclusive rights to market and sell Bedford, Mass.-based Insulet’s OmniPod system north of the border.
Seahorse Bioscience Inc. wrapped up its latest funding round — the North Billerica, Mass.-based company’s fourth — pulling in $5 million.
Investors included Commonwealth Capital Ventures, HLM Venture Partners, Rock Maple Ventures, Oxford Bioscience Partners and HLM Venture Partners, all Boston-area venture capital funds. Atlanta-based Life Sciences Partners, New York-based New Science Ventures and Healthcare Ventures of Princeton, N.J., also returned for the deal.
MassDevice Network
@MassDevice
LinkedIn
YouTube